Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | IMW 2019: the promising introduction of new treatment strategies

Paul Richardson • 14 Sep 2019
IMW 2019
Multiple Myeloma GSK-916 Melflufen Melphalan

Dr Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the recent presentation of novel therapies at the International Myeloma Workshop (IMW) 2019, in Boston, MA. Particularly, he highlights the use of antibody-drug conjugates and targeted therapeutics.

More from Paul Richardson

1:35
Novel therapeutic options and quadruplet regimens for newly diagnosed multiple myeloma
Paul Richardson • 29 Sep 2023
2:51
ANCHOR and LIGHTHOUSE trials: melflufen in multiple myeloma
Paul Richardson • 29 Sep 2023
7:24
Session highlights: managing the aging population in myeloma & promising treatment options
Paul Richardson • 29 Sep 2023
2:59
Exploring the potential role of melflufen in myeloma & updates from the LIGHTHOUSE trial
Paul Richardson • 12 May 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals